Utnal Preeti Ashok, A Hemalatha, Pn Sreeramulu, Gn Manjunath
Department of Pathology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India.
Department of Surgery, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India.
Asian Pac J Cancer Prev. 2020 Oct 1;21(10):3055-3059. doi: 10.31557/APJCP.2020.21.10.3055.
CD133 is a commonly used cancer stem cell (CSC) marker in breast cancer. However, the association between CD133 expression, with clinicopathological features and prognosis in breast cancer, is poorly understood in the Indian subcontinent. This study was designed to explore the expression of CD 133 in breast carcinoma and to know its association between CD133 and clinicopathological characteristics.
A total of fifty seven cases were included in the study. All the clinicopathological parameters were collected from Department of Pathology archives. Slides, blocks, clinical information, tumor size and axillary lymph node status were obtained from medical records and the pathology reports. Immunohistochemistry was done using CD 133 antibodies. Both Cytoplasmic and membranous staining was taken a positive. Scoring was done based on percentage of positive cells and intensity of staining. MS Excel, SPSS version 22 (IBM SPSS Statistics, Somers NY, USA) was used to analyze data.p value < 0.05 was considered as statistically significant.
Statistically significant association between the CD 133 expression and nodal metastasis, tumor stage and Nottingham prognostic index was analysed. There was no statistical correlation between CD 133 expression age, tumor grade and tumor size. The disease free survival showed the mean disease free survival of CD 133 positivity cases was 16months. And the patients who were negative for CD 133 expression had mean survival of 30 months. By the Kaplan Mayer graph it was evident that the more the CD 133 expression the lesser was the disease free survival of the patients.
CD 133 expression was seen in 77.08% cases and was associated with tumor stage, lymph node metastasis, poor Nottingham prognostic index and worse disease free survival. An increasing trend of association was seen between CD 133 expression and Age, Tumor Size and Tumor grade.
.
CD133是乳腺癌中常用的癌症干细胞（CSC）标志物。然而，在印度次大陆，人们对CD133表达与乳腺癌临床病理特征及预后之间的关联了解甚少。本研究旨在探讨CD133在乳腺癌中的表达情况，并了解其与临床病理特征之间的关联。
本研究共纳入57例病例。所有临床病理参数均从病理科档案中收集。玻片、组织块、临床信息、肿瘤大小和腋窝淋巴结状态均从病历和病理报告中获取。使用CD133抗体进行免疫组织化学检测。细胞质和细胞膜染色均为阳性。根据阳性细胞百分比和染色强度进行评分。使用MS Excel、SPSS 22版（IBM SPSS Statistics，美国纽约州萨默斯）进行数据分析。p值<0.05被认为具有统计学意义。
分析了CD133表达与淋巴结转移、肿瘤分期和诺丁汉预后指数之间的统计学显著关联。CD133表达与年龄、肿瘤分级和肿瘤大小之间无统计学相关性。无病生存期显示，CD133阳性病例的平均无病生存期为16个月。而CD133表达阴性的患者平均生存期为30个月。通过Kaplan Mayer图可以明显看出，CD133表达越高，患者的无病生存期越短。
77.08%的病例中可见CD133表达，其与肿瘤分期、淋巴结转移、不良的诺丁汉预后指数及较差的无病生存期相关。CD133表达与年龄、肿瘤大小和肿瘤分级之间存在增加的关联趋势。
